Orgovyx (Relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist used for the treatment of adult patients with advanced prostate cancer.
Dosage: Start therapy of Relugolix with a loading dose of 360 mg on the first day and continue therapy with a 120 mg dose taken orally once daily at around the same time each day. Relugolix tablets can be administered with or without food. Instruct patients to swallow tablets whole and not to crush/chew tablets. Advise patients to administer a missed dose of Relugolix as soon as they remember. If the dose was missed by over 12 hours, patients should not administer the missed dose and resume with the upcoming scheduled relugolix dose. If therapy with Relugolix is interrupted for more than 7 days, restart Relugolix with a loading dose of 360 mg on the first day, and continue with a dose of 120 mg once daily.
Side Effects: The most commonly reported orgovyx side effects include:
- Hot flush
- Glucose increased
- Triglycerides increased
- Musculoskeletal pain
- Hemoglobin decreased
- Alanine aminotransferase (ALT) increased
- Aspartate aminotransferase (AST) increased
Warnings and Precautions:
- In patients with orgovyx tablets, the periodic monitoring of electrolytes as well as electrocardiograms should be considered.
- Monitor therapeutic effect of relugolix 120 mg by measuring serum concentrations of prostate specific antigen (PSA) periodically. If PSA increases, monitor the serum concentrations of testosterone.
- Patients with relugolix should contact their health specialist immediately for signs or symptoms of QT prolongation.
- Use of orgovyx 120 mg can be harmful to a developing fetus and can cause loss of pregnancy.
- Male patients with female partners of reproductive age should use effective contraception during therapy and for 2 weeks after the last dose of relugolix.